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ABSTRACT
The Direct-to-Consumer Advertising (DTCA) of pharmaceutical firms has been defined as an attempt of
pharmaceutical companies to advertise products directly to patients (comsumers). Pharmaceutical DTCA has been
criticized due to its inappropriateness and some urged the need to strengthen regulations. The DTCA has an impact
on the public from both a benefit and harm concern. The purpose of this study is to investigate the current trend of
pharmaceutical DTCA in the US and its effect on patients, physicians, and drug utilization. The methodology used in
the research is literature review and semi-structured interview. The pharmaceutical DTCA showed reduction in total
spending with the television advertising as the biggest channel of DTCA. The small channel market o f advertising was
the online approach where three-digit growth of 109% was demonstrated. The DTCA affected the physician-patient
relationship as well as patient satisfaction. Patients who received the medication associated with DTCA showed
higher satisfaction by 43% compared to those receiving other medications. The under-diagnosed conditions, such as
depression, could potentially benefit from pharmaceutical DTCA by increasing the awareness regarding those
diseases. The advertising of Tegaserod, a medication for irritable bowel syndrome indicated the increasing
awareness of the disease along with increasing numbers of Tegaserod prescriptions. The increase of drug utilization
by pharmaceutical DTCA seemed to be beneficial in the treatment of benign prostatic hypertrophy. The advertising
of second line drugs resulted in an increase of the first line drug utilization by two times compared to the second line
drug utilization. The benefit of pharmaceutical DTCA included enhancing appropriate drug utilization by increasing
awareness due to diseases such as benign prostatic hypertrophy. The DTCA might cause potential harm by
interfering with a physician’s decision regarding prescription drug choice. Additional studies should focus on the
type and content of DTCA. The limitation of the study was lack of available data on pharmaceutical DTCA spending
to the public.
INTRODUCTION
The Direct-to-Consumer Advertising (DTCA) of pharmaceutical firms has been defined as an attempt of
pharmaceutical companies to advertise or promote information regarding a prescription drug directly to patients. The
DTCA can be performed through a variety of advertising channels including, television broadcast, billboards, and
consumer magazines (Abel et al., 2006).
There have been many types of DTCA, which have included: “help-seeking ads”, “reminder ads”, and
“product claim ads.” (Ventola, 2011) The “help-seeking ad” type has been categorized by a presence of only
information regarding to disease and omitted the drug information. The “reminder ad.” p rovided limited information
regarding prescription medicine, such as the name of drug, pricing, and strength; however, this type of advertisement
did not provide the indication or any claim on efficacy or any drug effects (Gellad & Lyles, 2007). The “produ ct claim
ad.” was the advertisement that involved in more holistic provision of a prescription drug information compared with
the other types of advertisement. This type of advertisement provided the indication, efficacy, and safety profile of
the prescription drug (Connors, 2009). Even though some countries have allowed limited prescription drug
advertisement, the US and New Zealand are the only two countries that have “product claim ad” type widely advertised
on television and other broadcasting media (Abel et al., 2006; Vats, 2014).
The broadcast of prescription drugs via television has become more popular since the loosening of Food and
Drug Administration (FDA) regulation on DTCA in 1997 (Morgan, 2007). The expenditure of DTCA was higher than
$4 billion in 2004 and showed 23% growth compared to the previous year (Gellad & Lyles, 2007). Even though the
total spending of prescription drugs promotion had declined between 2006 and 2010, DTCA had been criticized
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continuously due to appropriateness and legal issues. For example, DTCA generally associated with black box
warning of prescription drugs that may cause serious side effect (Arnold & Oakley, 2013). The purpose of DTCA
mainly focused on the commercial oriented patient rather than intended to educate p atient. The DTCA has generally
targeted at a limited range of drugs. In 2000, 20 of the top products in pharmaceutical industry accounted for 60% of
total spending in DTCA. Furthermore, the advertisement of a single medication, Vioxx cost $161 million in 2 000,
which surpassed many of advertisement expenses for consumer products such as Dell computers, Budweiser, Pepsi,
and Nike (Rosenthal, Berndt, Donohue, Frank, & Epstein, 2002). After the discovery of serious side effects of Vioxx,
including stroke and myocardial infarction, it has been withdrawn from the market since September 2004 (Schuchman,
2007).
Many critics have addressed that DTCA has been under-regulated and urged the need to strengthen rules and
regulations (Donahue, Cervasco, & Rosenthal, 2007). For example, the advertisement of prescription drugs required
no approval or any pre-clearance before the time of broadcasting. In the case where any violations of FDA regulation
occurred, the FDA could request for revisions of the advertisement; however, it would not change the fact that
consumers may already had exposure to inappropriate advertisement and might be misled by those information (Shaw,
2008). The guidance for DTCA established by the FDA has also been seen as unclear. For instance, the guidance
regulated the pharmaceutical company to include only “the most serious and the most common” for their products has
allowed the pharmaceutical companies to decide which associated risk(s) to be disclosed in their advertisement
(Biegler & Vargas, 2013). Furthermore, the establishment of DTCA guidance has generally been delayed for many
years. The draft of the new guidance regarding risk communication was created as a draft version since 2004 but was
never been revised until 2015 (Christopher & Robertson, 2015).
The DTCA impacts the public in both favorable and harmful ways (Almasi, Stafford, Kravitz, & Mansfield,
2006). The benefits of DTCA for the public have included: more empowered patients, enhancement of the patient physician relationship, and made awareness more apparent to the patients, especially for underdiagnoses conditions
(Delbaere & Smith, 2006). On the other hand, the opposing position claimed that DTCA led to many drawbacks,
which have included: misled patients regarding drug information, interference with physician decision in prescribing,
and drug overutilization (Ventola, 2011).
Per the Centers for Medicare & Medicaid Service (CMS), prescription drugs costs have risen to $297.7 billion
in 2014, with 12.2% growth rate compared to 2013 (CMS, 2014). The rising health care expenditure has been one of
the most problematic issues in the U.S. health care environment. The growing trend of DTCA could worsen the
situation of cost containment especially for prescription drug cost (Donahue et al, 2007).
The purpose of this research was to observe the current practice of DTCA in the US and observed the effect
of DTCA by pharmaceutical firm, especially on patients, physicians, and drug utilization.
METHODOLOGY
The hypothesis of the research was that DTCA may be one of the reasons that drive health care cost in the
U.S. by provoking inappropriate drug utilization. The methodology for this research is literature review and semistructured interview. A systematic literature review was performed as following: (1) identify relevant database and
key words, and accessing the primary search results and the appropriateness of key words and literatures; (2)
established inclusion criteria and selected the literature based on these criteria; (3) categorization of the literature
review results.
Step 1: Literature Search and Collection
Four of electronic databases were used for literature review: Marshall University Ebscohost database,
ScienceDirect, Pubmed, and Google Scholar. Keywords included: direct-to-consumer advertising and
expenditure/spending, DTCA and expenditure or spending, prescription drug advertising, DTCA and drug utilization,
DTCA and effect, and prescription drug and spending.
Step 2: Literature Analysis and Inclusion Criteria
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The inclusion criteria were literature written in English, research study that conducted in the North America
or New Zealand, and published year from 2000 to 2016. The literature published from 2006 or later was more favorable
since provided a more recent trend in DTCA promotion over the past ten years. A total of 87 articles were found and
39 of those have been included in this review.
Step 3: Literature Categorization
The selected literatures were categorized based on conceptual framework and based on the subheadings,
which included: The Emerging of Online DTCA and Trend for Pharmaceutical Advertising; Prescrip tion Drug
Coupons, a new form of DTCA; DTCA Effect Relationship between Patient and Physician and Patient’s Satisfaction;
and The DTCA and Drug Utilization.
A semi-structure structured interview was performed via e-mail. The interviewee is a physician that has
engaged in prescribing medication for longer than 20 years in the U.S. The answer has been reviewed by the researcher
and excluded any unrelated information.
Figure1: Conceptual framework

Trend in DTCA
-

DTCA spending
PDC
Internet-based DTCA

Patient-physician relationship
and

Increase drug utilization

Inappropriate prescription

Appropriate prescription
RESULTS

The Emerging of Online DTCA and Trend for Pharmaceutical Advertising
With the growing of internet-based information, consumers have started to actively search for information
through online channel including for medical information. The expenditure of internet -based pharmaceutical
advertising or eDTCA has been expected to gain double-digit growth between 2010-2015 (Liang & Mackey, 2011).
The advantage of eDTCA was the ability to spread the advertisement globally via multiple channels such as website,
satellite TV, and social media (Mintzes, Morgan, & Wright, 2009).

Business and Health Administration Association Annual Conference 2017

Page 289

Mackey, Cuomo, and Liang (2015) conducted a research study to investigate the information regarding to
DTCA expense by pharmaceutical firms from 2005 to 2009. The data were collected from multiple marketing data
firms such as IMS health, Nielsen Co., Cegedim Strategic Data, and Kantar Media. The data was analyzed for total
spending of DTCA and spending for each DTCA sub-category, which included television, print media, radio, outdoor
ads, and internet (eDTCA). The total spending of DTCA by pharmaceutical firms decreased from $4.8 billion in 2005
to $4.4 billion in 2009 and showed 7.83% declined during 2005 to 2009. The biggest spending of DTCA sub -category
in this period was television with approximately $2.9 billion in 2009 however, this channel showed decrease i n
spending with 13.20% from 2005 to 2009. Even though eDTCA sub-category accounted for small amount of spending
in total DTCA but experienced three-digit growth at 109 % in the same period. (Mackey et al., 2015).
DTCA category

2005 expenditure

2009 expenditure

Change (%)

Television

$3,390,587,472

$2,943,000,894

-13.20

Print media + radio + outdoor
ads
Internet

$1,396,225,125

$1,403,438,560

0.52

$56,180,283

$117,403,346

108.98

Total DTCA

$4,842,992,880

$4,463,842,800

-7.83

Table1: DTCA expenditure in 2005 and in 2009 (Kornfield et al., 2015)
Kornfield et al. (2015) reported a significant decrease in household exposure to DTCA via television from
2007 to 2013. The average of televised DTCA household exposure was 195.3 times per month in 2007 compar ed with
111.1 times per month in 2011, indicated 43% reduction from 2007 to 2013. However, the household exposure of
DTCA for depression medication increased from 8.6 times per month in 2007 to 11.3 times per month in 2011
(Kornfield et al., 2015). The reduction in televised DTCA might result from the emerging of online media
advertisement (Liang & Mackey, 2011).
The overall cost of pharmaceutical promotion spending reached its peak of $36.1 billion in 2004 and has
declined gradually from 2005 to $27.7 billion in 2010. The cost of DTCA promotion has had a similar trend but
reached its peak of $5.9 billion in 2006 and followed by declining to $4.4 billion in 2010. The electronic promotion
was the only promotional category that has been described by growth in expense despite of small amount of portion
in overall promotional cost (Kornfield, Donohue, Berndt, & Alexander, 2013).
Prescription Drug Coupons, a New Form of DTCA
The Prescription Drug Coupons (PDC) was a novel form of pharmaceutical marketing that offered special
discounts for branded drugs to patients who had private insurance or the patients who paid out -of-pocket (Gagnon &
Lexchin, 2008). The ideal goal of PDC was to alleviate the burden of cost regarding too expensive branded drug that
might result in non-adherence and further complications. The PDC could be gained through variety of media such as
pamphlets in physician office, website, and eCoupons (Grande, 2012).
The PDC generally has been associated with the promotion of expensive branded drugs. The result of
searching by using key words “prescription drug coupon” with Google showed an outcome of 9 products from top -10
selling drug during November 2011 to November 2012. Six out of ten founded products also labeled with black box
warnings that related to potential for serious complications (Grande, 2012). Furthermore, the question was raised
whether PDC would lead to lower prescription drug expenditures or appropriate use of medication in a long run or not
(Gagnon & Lexchin, 2008). For example, Lipitor was one of the products engaged in PDC that offered the high
discount at $75 per month in 2014 and would result in $1119.6 cost per year in 2014. However, Lipitor could be
replace by generic product with a total cost of $192 per year in 2014 and provided substantial saving of $927.60 per
year in 2014 compared with the cost of Lipitor (Mackey, Yagi, & Liang, 2014). Bhutada, Cook, and Perri (2009)
found that patients who exposed to PDC advertising were more likely to ask physicians for specific prescription drugs
and showed more favorable attitude toward those products.

Business and Health Administration Association Annual Conference 2017

Page 290

DTCA Effect Relationship between Patient and Physician and Patient’s Satisfaction
The unique marketing promotion of DTCA had altered the way patient and physician interacted with each
other in the US health care system (Potter & McKinlay, 2005). The DTCA exposure has increased patient’s demand
for specific prescription by increase the chance patients would ask their physician regarding to those drugs.
Additionally, these authors also showed that 43% of patient, who mentioned DTCA drugs during last physician office
visit, received medication they requested (Weissman et al., 2004).
The effect of DTCA on patient satisfaction might vary due to age and severity of conditions (Blose & Mack,
2009). A study conducted by using vignettes indicated that denial of patient’s request for specific prescription affected
patient satisfaction, trust, and commitment; however, the expectation of receiving prescription did not affect those
factors. (Shah, Bentley, & McCaffrey, 2006).
Lewin (2013) studied the factor that affected patient satisfaction in patient groups who discussed information
from DTCA with their physicians. The data were collected via random-digit telephone interview. The result showed
that receiving diagnosis was not associated with increase patient’s satisfaction but receiving prescription was
associated with higher patient’s satisfaction. Furthermore, patients who received prescription related to DTCA were
more likely to report higher satisfaction by 42.2% compared with those who received other prescription. Finally,
patients who did not receive prescription related to DTCA was more likely to have higher satisfaction if there were
acknowledged by some kind of explanations regarding to the denial (Lewin, 2013).
The DTCA and Drug Utilization
The DTCA has encouraged patient to seek for treatment with physicians especially for under -diagnosed
condition and condition associated with social stigma such as depression (Holmer, 2002). On the contrary, the DTCA
has led to over diagnosis and drug over utilization that might ultimately result in increase of adverse drug reaction
(Ross, & Kravitz, 2013). Eventually, there has been no sufficient evidence to identify whether the DTCA would cause
more harm than benefit, vice versa (Mintzes, 2012; Law, Majumdar, & Soumerai, 2008).
Irritable bowel syndrome (IBS) was a chronic condition affected roughly 10% of the US population; however,
only small number of patients sought for treatment because of many reasons such as low public awareness, social
stigma, and absence of effective solution (Cremonini & Talley, 2005). Tegaserod was an effective medication for IBS
that was heavily marketed during 2005 to 2007 and was suspended from the market since March 2007 due to its
significant risk of heart conditions (US FDA, 2008). The DTCA of tegaserod increased the awareness of IBS,
increased the physician visits, and increased number of prescription for tegaserod (Dorn, Farley, Hansen, Shah, &
Sandler, 2009).
The effect of DTCA that increased the number of prescription could be seen in many product classes included
statins, H2 receptor antagonists, and triptans. The beneficial outcome of the DTCA on increase prescription has been
ambiguous and might be difficult to evaluate. In other word, if the increase in prescription has resulted from more
awareness and using of first line medication, the DTCA would be consider beneficial; conversely, it would be
detrimental if the DTCA promoted inappropriate use of second line medication (Skeldon, Kozhimannil, Majumdar,
& Law, 2015).
Tamsulosin (Flomax) and dutasteride (Adovart) were first line and second line medications for benign
prostatic hypertrophy respectively. Skeldon et al. (2015) investigated the expenditure o f DTCA, web search interest,
and drug utilization for both drug from January 2003 to December 2007. The DTCA spending for tamsulosin was
$139 million for the period of 2003 to 2007 and for dutasteride was $231 million from 2003 to 2007. The effect of
both campaigns tamsulosin and dutasteride resulted in aggregate increase of both product awareness, which detected
by web search interest, and drug utilization. For example, the DTCA of dutasteride (second line medication) not only
increased the utilization trend of dutasteride but also increased the utilization of tamsulosin (first line medication)
nearly two times compared to dutasteride. Thus, the DTCA of competing products was likely to show beneficial
outcome of increase appropriate prescription by increase in awareness rather than inappropriate use of second line
medication (Skeldon et al., 2015)
DISCUSSION

Business and Health Administration Association Annual Conference 2017

Page 291

The practice of DTCA in the U.S. has been criticized by those who both supported and opposed DTCA.
However, it is highly unlikely that DTCA will fade away in pharmaceutical advertising practice in the US. The result
from Mackey et al. (2015) has showed slight decrease in overall spending of DTCA of 7.83 % during 2005 to 2009,
but this decrease was likely to have been caused by shifting from one type of D TCA to another less expensive form
of DTCA. The television channel served as the most important channel of DTCA since it consisted of approximately
65% of total spending with $2.9 billion in 2009. The television sub-category experienced a decrease of 13.20% during
2005 to 2009, while the internet sub-category demonstrated an increase by 108.98% in the same period. It was possible
that the effort of pharmaceutical company to advertise its product directly to a patient remained the same or even
higher but shifting to online channel with less costs and more effectiveness. Liang and Mackey (2011) also reported
the internet was the most popular source among consumers who are searching for health-related information.
The PDC was another trend that emerged in DTCA in the U.S. that might cause detrimental effects to patients
since it is involved with black box warning for prescription drugs. Even though the pharmaceutical company claimed
that PDC aimed to promote accessibility and adherence to medication but it was more likely for extending product
life cycle since the majority of prescription drugs available with PDC were patent expired or close to patent expiration
date. If the trend of PDC became more popular it might increase the cost of prescription drug by pro moting more
expensive drugs, especially brand name that could be substituted with lower cost generic drugs regardless of
discounting.
The DTCA seemed to affect the way a patient and physician interacted to each other. The DTCA increased
demand for specific drugs and patients have been engaged in mentioning specific medications to their physicians.
Furthermore, those who received the medication they mentioned to their physician showed greater satisfaction than
others who did not (Lewin, 2013; Weissman et al., 2004). This situation could put a pressure on the physician who
wished to satisfy their patient and lead into inappropriate prescribing and thus, result in increased unsuitable drug
utilization. A survey of physicians also reported that DTCA resulted in increased some of the inappropriate
prescription volume and affected the prescribing pattern (Robinson et al., 2004).
The DTCA could increase the drug utilization by increase the awareness of a patient regarding to disease
especially a condition that associated with social stigma. However, this increase of drug utilization had both beneficial
and harmful consequences. Tegarserod prescription prescribing increased by the effect of DTCA and has been
withdrawn from the market since 2007 due to significant risk of heart conditions. This similar issue was also found
earlier with the Vioxx in 2004. There was no strict regulation for DTCA on the new drugs that full safety profile has
not been established (Liang & Mackey, 2011).
On the other hand, the beneficial effect on DTCA has been seen in the case of tamsulosin and dutasteride.
The promotion of dutasteride, which was the second line therapy of benign prostatic hyperplasia, resulted in increased
awareness of the condition and the increase in prescription volume of tamsulosin, which is the first line therapy. Thus,
the promotion of dutasteride through DTCA could be seen as beneficial by increasing diagnosis and increase
appropriate drug utilization.
Todd W. Gress, MD, an associate professor for internal medicine at School of Medicine, Marshall University.
As an interviewee in this study, he shared some concern regarding DTCA by pharmaceutical firms in the US. He
stated that the DTCA could have a significant impact on the health care system since it enhances awareness to the
public of devices or therapies that were generally very expensive and may not be the standard of care for specific
disease processes. He also recalled one patient that requested a new oral anticoagulant based on DTCA. This situation
led to more consumption in time at the office visit because of the physician needing to justify that this medication may
not suitable for this patient. Dr. Gress also believed that exposure to DTCA encouraged conversations between patients
and physicians, yet could push the physicians against their better judgment and prescribed the new medication. The
DTCA might cause potential harm; primarily by diminishing the time involved in discussion the DTCA information
brought by the patient to the visit. The DTCA regarding only one option of treatment was a very biased narrow
approach to begin with and its primary intent was more likely as financial gain for the pharmaceutical company.
The trend of DTCA continues growing and resulting in increased drug utilization through multiple
mechanisms, which included increase demand of the patient for specific drug, increase awareness regarding to under diagnosed condition, and promoting dialogue between physician and patient. The content for each DTCA might affect
the different outcomes regarding the appropriateness of drug utilization.
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Future studies should focus on the type and content of DTCA and the proper use of prescription drugs.
Furthermore, retrospective study can be performed to investigate the correlation between DTCA spending and health
care expenditure among different countries. The limitation of this study included limited current information of DTCA
spending from the pharmaceutical company that available to the public. There was lack of the quantitative data on the
effect of pharmaceutical DTCA, thus making it difficult to evaluate the actual effect of DTCA on drug utilization.
Additionally, DTCA is a very subjective topic which is based on individual opinion. It can affect research bias and
bias from the interviewee.
CONCLUSION
The online channel was a critical advertising portal for DTCA by pharmaceutical firms. The DTCA of
pharmaceutical company indicated mixed results of potential benefit and harm. For example, the DTCA by
pharmaceutical firm enhanced the awareness of patient to under-diagnosed condition such as benign prostatic
hypertrophy; however, it could increase the prescription drug cost by promoting expensive branded drugs.
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